KR101326679B1 - 폴리글리세릴-2 디폴리하이드록시스테아레이트로안정화시킨 산화 아연을 포함하는 기저귀 발진 완화용 또는치료용 외용제 조성물 - Google Patents
폴리글리세릴-2 디폴리하이드록시스테아레이트로안정화시킨 산화 아연을 포함하는 기저귀 발진 완화용 또는치료용 외용제 조성물 Download PDFInfo
- Publication number
- KR101326679B1 KR101326679B1 KR1020070123385A KR20070123385A KR101326679B1 KR 101326679 B1 KR101326679 B1 KR 101326679B1 KR 1020070123385 A KR1020070123385 A KR 1020070123385A KR 20070123385 A KR20070123385 A KR 20070123385A KR 101326679 B1 KR101326679 B1 KR 101326679B1
- Authority
- KR
- South Korea
- Prior art keywords
- diaper rash
- zinc oxide
- polyglyceryl
- dipolyhydroxystearate
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 206010012444 Dermatitis diaper Diseases 0.000 title claims abstract description 50
- 208000003105 Diaper Rash Diseases 0.000 title claims abstract description 50
- 239000011787 zinc oxide Substances 0.000 title claims abstract description 30
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 28
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 14
- 229960000458 allantoin Drugs 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 7
- 229940002386 calendula officinalis extract Drugs 0.000 claims description 7
- 208000010201 Exanthema Diseases 0.000 claims description 5
- 201000005884 exanthem Diseases 0.000 claims description 5
- 206010037844 rash Diseases 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 239000004094 surface-active agent Substances 0.000 abstract description 12
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 abstract description 10
- 235000003880 Calendula Nutrition 0.000 abstract description 10
- 230000000087 stabilizing effect Effects 0.000 abstract description 4
- 241000132025 Calendula Species 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 29
- 238000009472 formulation Methods 0.000 description 18
- 239000000843 powder Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 15
- 239000006071 cream Substances 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 239000002537 cosmetic Substances 0.000 description 11
- 240000001432 Calendula officinalis Species 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 241000222122 Candida albicans Species 0.000 description 7
- 229940095731 candida albicans Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000589516 Pseudomonas Species 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 229940008099 dimethicone Drugs 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000010478 argan oil Substances 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010027627 Miliaria Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000008384 inner phase Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000009849 vacuum degassing Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
구분 | 성분 | 실시예1 | 비교예1 | 비교예2 | 비교예3 |
수상 성분 | 1. 정제수 | 잔량 | 잔량 | 잔량 | 잔량 |
2. 글리세린 | 5.0 | 5.0 | 5.0 | 5.0 | |
3. 부틸렌글리콜 | 2.0 | 2.0 | 2.0 | 2.0 | |
4. 트리에탄올아민 | 0.18 | 0.18 | 0.18 | 0.18 | |
5. 디소듐이디티에이 | 0.02 | 0.02 | 0.02 | 0.02 | |
유상성분 | 6.아르간 오일 (Argan Oil) | 2.0 | 2.0 | 2.0 | 2.0 |
7.호호바 오일(Jojoba Oil) | 2.0 | 2.0 | 2.0 | 2.0 | |
8.산화 아연 | 20.0 | 20.0 | 20.0 | 20.0 | |
9.폴리글리세릴-2 디폴리하이드록시스테아레이트(Polyglyceryl-2 Dipolyhydroxystearate) | 3.0 | - | - | - | |
10.폴리글리세릴-2 세스퀴아이소스테아레이트(Polyglyceryl-2 Sesquiisostearate) | - | 3.0 | - | - | |
11.세틸 피이지/피피지-10/1 디메치콘(CetylPEG/PPG-10/1 Dimethicone) | - | - | 3.0 | - | |
12.피이지-7 디메치콘 (PEG-7 Dimethicone) |
- | - | - | 3.0 | |
13. 카보머 | 0.3 | 0.3 | 0.3 | 0.3 | |
14. 향 | 적량 | 적량 | 적량 | 적량 | |
15. 방부제 | 적량 | 적량 | 적량 | 적량 |
성분 | 실온 | 고온(45℃) | 파우더 분산성 |
1. 실시예 1 | 한달 이상 안정 | 한달 이상 안정 | 고르게 분산 유지 |
2. 비교예 1 | 14일만에 분리 | 5일만에 분리 | 엉김 |
3. 비교예 2 | 10일만에 분리 | 3일만에 분리 | 엉김 |
4. 비교예 3 | 제조 직후 분리 | 제조 직후 분리 | 엉김 |
구분 | 성분 | 실시예 2 | 실시예 3 |
수상 성분 |
1. 정제수 | 잔량 | 잔량 |
2. 글리세린 | 5.0 | 5.0 | |
3. 부틸렌글리콜 | 2.0 | 2.0 | |
4. 트리에탄올아민 | 0.18 | 0.18 | |
5. 디소듐이디티에이 | 0.02 | 0.02 | |
유상 성분 |
6.아르간 오일 (Argan Oil) | 2.0 | 2.0 |
7.호호바 오일(Jojoba Oil) | 2.0 | 2.0 | |
8.산화 아연 | 20.0 | 40.0 | |
9.폴리글리세릴-2 디폴리하이드록시스테아레이트 (Polyglyceryl-2 Dipolyhydroxystearate) |
3.0 | 3.0 | |
10.알란토인 | 0.5 | - | |
11.카렌듈라 추출물 | 1.0 | - | |
12. 카보머 | 0.3 | 0.3 | |
13. 향 | 적량 | 적량 | |
14. 방부제 | 적량 | 적량 |
균주 | 시료 | 초기 균수 | 24시간후 균수 | 균 감소율 |
칸디다 알비칸스 ATCC 14053 |
대조군 | 1.4 x 105 | 7.2 x 106 | |
실시예 1 | 1.4 x 105 | <100 | 99.9% | |
실시예 2 | 1.4 x 105 | <100 | 99.9% | |
실시예 3 | 1.4 x 105 | <10 | 99.9% | |
슈도모나스 애루지오노사 ATCC 27853 |
대조군 | 1.2 x 105 | 5.5 x 106 | |
실시예 1 | 1.2 x 105 | <100 | 99.9% | |
실시예 2 | 1.2 x 105 | <100 | 99.9% | |
실시예 3 | 1.2 x 105 | <10 | 99.9% | |
포도상구균 ATCC 12228 |
대조군 | 1.5 x 105 | 6.8 x 106 | |
실시예 1 | 1.5 x 105 | <100 | 99.9% | |
실시예 2 | 1.5 x 105 | <100 | 99.9% | |
실시예 3 | 1.5 x 105 | <10 | 99.9% |
시료 | 응답자 수 | |||
매우 양호 | 양호 | 보통 | 미흡 | |
실시예 1 | 18 | 8 | 4 | 0 |
실시예 2 | 20 | 7 | 3 | 0 |
실시예 3 | 25 | 4 | 1 | 0 |
Claims (5)
- 산화아연 및 폴리글리세릴-2 디폴리하이드록시스테아레이트(Polyglyceryl-2 Dipolyhydroxystearate)를 포함하는 기저귀 발진 완화용 또는 치료용 외용제 조성물.
- 제 1항에 있어서, 상기 조성물은 알란토인(Allantoin) 및 카렌듈라 추출물(Calendula Officinalis Extract)로 이루어진 군에서 선택된 1종 이상을 더 함유하는 것임을 특징으로 하는 기저귀 발진 완화용 또는 치료용 외용제 조성물.
- 제 1항에 있어서, 상기 산화 아연(Zinc Oxide)은 조성물 총 중량에 대하여 0.001 내지 60 중량%로 함유됨을 특징으로 하는 기저귀 발진 완화용 또는 치료용 외용제 조성물.
- 제 1항에 있어서, 상기 폴리글리세릴-2 디폴리하이드록시스테아레이트 (Polyglyceryl-2 Dipolyhydroxystearate)는 조성물 총 중량에 대하여 0.001 내지 20 중량%로 함유됨을 특징으로 하는 기저귀 발진 완화용 또는 치료용 외용제 조성물.
- 제 2항에 있어서, 상기 알란토인(Allantoin) 또는 카렌듈라 추출 물(Calendula Officinalis Extract)은 조성물 총 중량에 대하여 각각 0.001 내지 20 중량%로 함유됨을 특징으로 하는 기저귀 발진 완화용 또는 치료용 외용제 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070123385A KR101326679B1 (ko) | 2007-11-30 | 2007-11-30 | 폴리글리세릴-2 디폴리하이드록시스테아레이트로안정화시킨 산화 아연을 포함하는 기저귀 발진 완화용 또는치료용 외용제 조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070123385A KR101326679B1 (ko) | 2007-11-30 | 2007-11-30 | 폴리글리세릴-2 디폴리하이드록시스테아레이트로안정화시킨 산화 아연을 포함하는 기저귀 발진 완화용 또는치료용 외용제 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090056299A KR20090056299A (ko) | 2009-06-03 |
KR101326679B1 true KR101326679B1 (ko) | 2013-11-08 |
Family
ID=40987719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070123385A Active KR101326679B1 (ko) | 2007-11-30 | 2007-11-30 | 폴리글리세릴-2 디폴리하이드록시스테아레이트로안정화시킨 산화 아연을 포함하는 기저귀 발진 완화용 또는치료용 외용제 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101326679B1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104547443A (zh) * | 2015-01-07 | 2015-04-29 | 杜小卫 | 婴儿复方护臀膏 |
KR20230090506A (ko) | 2021-12-15 | 2023-06-22 | 주식회사 시너지팜 | 황금 및 모란 뿌리 추출물을 포함하는 항균 조성물 및 이를 함유하는 위생용품 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5091193A (en) | 1989-08-23 | 1992-02-25 | Roussel Uclaf | Diaper rash treatment and compositions |
US6627178B1 (en) | 1999-07-30 | 2003-09-30 | Garret D. Cawthon | Methods, compositions and systems for the prevention and treatment of diaper rash |
US20040131704A1 (en) | 2003-01-03 | 2004-07-08 | Tammy Morse | A method of organic and all natural treatment, prevention and relief of diaper dermatitis and other related skin irritations. |
KR100560092B1 (ko) | 2000-12-15 | 2006-03-10 | 파트릭 프랑케 | 저알레르기성 및 비자극성 피부 보호 제제 |
-
2007
- 2007-11-30 KR KR1020070123385A patent/KR101326679B1/ko active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5091193A (en) | 1989-08-23 | 1992-02-25 | Roussel Uclaf | Diaper rash treatment and compositions |
US6627178B1 (en) | 1999-07-30 | 2003-09-30 | Garret D. Cawthon | Methods, compositions and systems for the prevention and treatment of diaper rash |
KR100560092B1 (ko) | 2000-12-15 | 2006-03-10 | 파트릭 프랑케 | 저알레르기성 및 비자극성 피부 보호 제제 |
US20040131704A1 (en) | 2003-01-03 | 2004-07-08 | Tammy Morse | A method of organic and all natural treatment, prevention and relief of diaper dermatitis and other related skin irritations. |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104547443A (zh) * | 2015-01-07 | 2015-04-29 | 杜小卫 | 婴儿复方护臀膏 |
KR20230090506A (ko) | 2021-12-15 | 2023-06-22 | 주식회사 시너지팜 | 황금 및 모란 뿌리 추출물을 포함하는 항균 조성물 및 이를 함유하는 위생용품 |
Also Published As
Publication number | Publication date |
---|---|
KR20090056299A (ko) | 2009-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Burlando et al. | Honey in dermatology and skin care: a review | |
CN109044915B (zh) | 一种婴幼儿护臀膏及其制备工艺 | |
CN108743474B (zh) | 一种油膏状宝宝护臀膏及其制备方法 | |
CN110638727B (zh) | 一种婴幼儿护臀组合物及其制备方法和应用 | |
KR102220534B1 (ko) | 수딩 크림 및 이의 제조 방법 | |
US7115287B2 (en) | Topical medicament and method of use | |
JPH06279256A (ja) | 皮膚外用剤 | |
KR20200053861A (ko) | 프로바이오틱스 발효물을 포함하는 항여드름 활성을 갖는 화장료 조성물 | |
CN114652884A (zh) | 一种山茶花舒缓精华液一次性卫生用品护理基材、制备方法及应用 | |
KR101458887B1 (ko) | 히카마, 콜리플라워, 말로우 및 아이슬란드 이끼 천연 복합추출물을 유효성분으로 함유하는 항산화, 보습, 피부 자극 완화 효과를 갖는 피부 개선용 화장료 조성물 | |
CN111437234A (zh) | 一种婴儿护臀霜 | |
CN112915055A (zh) | 一种舒缓多效除螨组合物及其应用 | |
KR101326679B1 (ko) | 폴리글리세릴-2 디폴리하이드록시스테아레이트로안정화시킨 산화 아연을 포함하는 기저귀 발진 완화용 또는치료용 외용제 조성물 | |
KR100879094B1 (ko) | 천연 정유 성분 및 그의 하이드로졸 성분을 함유하는 여드름 개선용 화장료 조성물 | |
US20230372425A1 (en) | Topical compositions containing manuka oil and palmarosa oil for treating skin conditions | |
WO2019194775A2 (en) | A composition for the treatment of diseases of nipple and areola | |
CN115364002A (zh) | 一种具有祛痘功效的粉底液及其制备方法 | |
US20170027881A1 (en) | Composition and related methods for treatment of pilosebaceous diseases | |
KR100892742B1 (ko) | 여드름 치료용 피부 외용제 조성물 | |
KR20170047515A (ko) | 그라비올라 항균 추출물을 함유하는 피부 활력 증진용 화장료 조성물 및 그 제조방법 | |
KR102723936B1 (ko) | 오소리 오일을 함유한 피부외용제 조성물 | |
CN118902933B (zh) | 一种可用于儿童湿疹的抑菌舒缓组合物及其制备方法及应用 | |
CN111686189B (zh) | 一种治疗红屁股的植物组合物及其应用 | |
KR102292487B1 (ko) | 코파이바 수지 추출물을 포함하는 여성 위생 관리용 조성물 | |
KR102587124B1 (ko) | 보습성 및 롤링성이 향상된 마사지용 화장료 조성물 및 이를 포함하는 젤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20071130 |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20120904 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20071130 Comment text: Patent Application |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20131028 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20131101 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20131104 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20161010 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20161010 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20181002 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20181002 Start annual number: 6 End annual number: 6 |
|
FPAY | Annual fee payment |
Payment date: 20190926 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20190926 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20200925 Start annual number: 8 End annual number: 8 |